BRIACELL THERAPEUTICS CORP. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
BRIACELL THERAPEUTICS CORP. (BCTX) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $1.79 million for the 12-month period ending 2024-07-31, per its 10-K filed 2024-10-29.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2024-10-29
- BRIACELL THERAPEUTICS CORP. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $1.79M, a 35.76% decline from fiscal 2023.
- BRIACELL THERAPEUTICS CORP. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $2.79M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2024-07-31 | $1.79M 10-K · filed 2024-10-29 |
| 2023-07-31 | $2.79M 10-K · filed 2023-10-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |